{"prompt": "['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 22 of 88', 'CCI']['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 23 of 88', '4', 'CLINICAL TRIAL DURATION AND TERMINATION', 'The planned clinical trial duration (from FSI to LSO) is approximately', 'The date of end', 'of the clinical trial is defined as the date of the last visit of the last subject who participates in the', 'trial.', 'The planned duration of recruitment (i.e. From FSI to LSI) is approximately CCI', 'Prior to subject enrolment, a screening period lasting', 'CC', 'at', 'the maximum is authorized.', 'Clinical trial participation for each subject is approximately CCI', 'GALDERMA may decide to prematurely terminate or suspend the participation of a particular', 'clinical trial center (e.g., for non-inclusion or non-compliance with protocol, regulations, or GCP)', 'or prematurely suspend the clinical trial (e.g., for safety, study drug quality, regulatory, efficacy,', 'or logistical reasons) at any time, with appropriate notification.', '5', 'SELECTION AND DISPOSITION OF CLINICAL TRIAL POPULATION', '5.1', 'Number of subjects', 'CCI', '5.2', 'Clinical trial population characteristics', 'In order to be eligible for the trial, subjects must fulfill all of the following criteria at Baseline visit.', 'Some criteria are to be checked at the Screening visit. Subjects may be re-screened once unless the', 'reason for screen failure is related to acne severity (IGA or PGA) or lesion counts.', '5.3', 'Inclusion criteria', '1.', 'The subject is a male or female, 9 years of age and older, at Screening visit.', '2.', 'Subject with clinical diagnosis of acne vulgaris,']['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 24 of 88', \"a) Investigator's Global Assessment (IGA) score of 3 (Moderate)\", 'CCI', 'b)', 'Truncal acne severity grade of 3 (moderate) on the Physician Global assessment (PGA)', 'scale CCI', '3.', 'In general good health (physical, mental, and social well-being, not merely the absence of', 'disease/infirmity), according to subject self-report.', '4.', 'Having Fitzpatrick skin phototype I-VI (refer to Fitzpatrick Skin Classification).', '5.', 'The subject is a female of non-childbearing potential (pre-menarcheal or postmenopausal', '[absence of menstrual bleeding for 1 year prior to Screening, without any other medical', 'reason], hysterectomy or bilateral oophorectomy).', '6.', 'The subject is a female of childbearing potential:', '6.1.', 'With a negative urine pregnancy test (UPT) at Screening and Baseline visits,', '6.2.', 'Who are willing to take UPTs throughout the course of the study.', '6.3.', 'Who has been strictly abstinent for 1 month prior to Screening/Baseline and agrees to', 'continue for the duration of the clinical trial and at least 1 month after the last study', 'drug application,', 'OR', 'Who agrees to use an effective and approved contraceptive method(s) for the duration', 'of the study and at least 1 month after the last study drug application. An effective', 'method of contraception is defined as:', '6.3.a.', 'bilateral tubal ligation;', '6.3.b.', 'approved combined oral contraceptives (estrogens and progesterone), implanted or', 'injectable contraceptives, or hormonal contraceptive vaginal rings with a stable', 'dose for at least 1 month prior to the Screening/Baseline visit;', '6.3.c.', 'hormonal intra uterine device (IUD) inserted at least 1 month prior to the', 'Screening/Baseline visit;', '6.3.d.', 'vasectomized partner for at least 3 months prior to the Screening/Baseline visit.', '7.', 'If a female of childbearing potential uses combined oral contraceptives approved as acne', 'treatments (e.g., Ortho Tri-Cyclen\u00ae, YazR, Diane-358, the dose should be stable for at', 'least 6 months prior to the Screening/Baseline visit.', '8.', 'For a pre-menstrual female who begins menses during the study:']\n\n###\n\n", "completion": "END"}